J&J’s Vitros 5600 system receives 510(k)
This article was originally published in The Gray Sheet
Executive Summary
Ortho-Clinical Diagnostics, a Johnson & Johnson company, plans in the fourth quarter to launch its Vitros 5600 next-generation laboratory diagnostics system, following receipt of 510(k) clearance Oct. 24. The device integrates clinical chemistry and immunoassay testing while incorporating "innovations" such as "sample-centered" processing and a small footprint, the firm explains. It can perform more than 100 different chemistry, immunoassay and infectious disease assays
You may also be interested in...
J&J's Vitros Lab Diagnostics Systems Expand Market Access, Drive Sales
Ortho-Clinical Diagnostics' Vitros 5600 and Vitros 3600 next-generation laboratory diagnostic systems will double the size of the market the Johnson & Johnson division addresses from $4.6 billion to $9.8 billion, according to the company
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.